RVMD
Revolution Medicines Inc.
Price performance
Sep 18, 2026About
Company activity
29 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 09/01 | RVMD | 8-K | Revolution Medicines, Inc. Announces Lease Agreement for New Headquarters | — | — | — |
| 08/26 | RVMD | 8-K | Revolution Medicines Receives FDA Approval for RASONQUE in Metastatic Pancreatic Adenocarcinoma | — | — | — |
| 08/05 | RVMD | 8-K | Revolution Medicines Files NDA for Daraxonrasib and Receives Breakthrough Therapy Designation | — | — | — |
| 06/22 | RVMD | 8-K | Revolution Medicines Announces Planned Retirement of President and Key Executive Changes | — | — | — |
| 05/06 | RVMD | 8-K | Revolution Medicines Announces Positive Daraxonrasib Trial Results and Strong Financial Position | — | — | — |
| 04/17 | RVMD | 8-K | Revolution Medicines, Inc. Issues $500 Million Convertible Senior Notes | — | — | — |
| 04/16 | RVMD | 8-K | Revolution Medicines Announces Major Equity Offering | — | — | — |
| 04/13 | RVMD | 8-K | Revolution Medicines Announces Positive Phase 3 Trial Results for Daraxonrasib in PDAC | — | — | — |
| 02/25 | RVMD | 8-K | Revolution Medicines Announces 2025 Financial Results and Corporate Progress | — | — | — |
| 11/05/25 | RVMD | 8-K | Revolution Medicines Announces Third Quarter 2025 Financial Results and Corporate Updates | — | — | — |
| 10/16/25 | RVMD | 8-K | Revolution Medicines Receives FDA Voucher for Daraxonrasib | — | — | — |
| 09/10/25 | RVMD | 8-K | Revolution Medicines Reports Positive Clinical Data for Daraxonrasib in Pancreatic Cancer Treatment | — | — | — |
| 08/06/25 | RVMD | 8-K | Revolution Medicines Announces Q2 2025 Financial Results and Progress | — | — | — |
| 06/27/25 | RVMD | 8-K | Revolution Medicines Announces Voting Results from Annual Meeting | — | — | — |
| 06/24/25 | RVMD | 8-K | Revolution Medicines Secures $2 Billion Funding Agreement with Royalty Pharma | — | — | — |
| 06/18/25 | RVMD | 8-K | Barbara Weber, M.D., Resigns from Revolution Medicines Board | — | — | — |
| 05/07/25 | RVMD | 8-K | Revolution Medicines Announces Q1 2025 Financial Results and Corporate Updates | — | — | — |
| 02/26/25 | RVMD | 8-K | Revolution Medicines Reports Q4 2024 Financial Results and Clinical Progress | — | — | — |
| 12/05/24 | RVMD | 8-K | Revolution Medicines Completes Public Offering | — | — | — |
| 12/02/24 | RVMD | 8-K | Revolution Medicines Updates Clinical Trials for RMC-6236 and RMC-6291 | — | — | — |
| 11/06/24 | RVMD | 8-K | Revolution Medicines Announces Third Quarter 2024 Financial Results and Corporate Updates | — | — | — |
| 10/25/24 | RVMD | 8-K | Revolution Medicines Announces Preliminary Clinical Data for RMC-9805 | — | — | — |
| 10/23/24 | RVMD | 8-K | Revolution Medicines Reports Updated Clinical Data for RMC-6236 in PDAC Patients | — | — | — |
| 08/07/24 | RVMD | 8-K | Revolution Medicines Announces Q2 2024 Financial Results and Appoints New Director | — | — | — |
| 07/15/24 | RVMD | 8-K | Revolution Medicines Updates on Financial Guidance and Clinical Progress for RMC-6236 | — | — | — |
| 06/24/24 | RVMD | 8-K | Revolution Medicines, Inc. Announces Voting Results from 2024 Annual Meeting | — | — | — |
| 05/08/24 | RVMD | 8-K | Revolution Medicines Reports Q1 2024 Financial Results and Corporate Update | — | — | — |
| 02/26/24 | RVMD | 8-K | Revolution Medicines Reports Q4 2023 Financial Results and Corporate Progress | — | — | — |
| 01/09/24 | RVMD | 8-K | Revolution Medicines Discloses Corporate Presentation and Pipeline Update | — | — | — |
RVMD filing record
Revolution Medicines Inc. (RVMD): 29 8-K filings summarized, the most recent on Sep 1, 2026.
What the 8-K filings said
- Sep 1, 2026 · medium impact
Revolution Medicines, Inc. has entered into a material definitive agreement to lease four buildings in Redwood City, California, totaling approximately 672,000 rentable square feet, as its new headquarters. The lease agreements, structured with four separate landlords, have staggered commencement dates starting…
Revolution Medicines, Inc. Announces Lease Agreement for New Headquarters - Aug 26, 2026 · high impact
Revolution Medicines, Inc. announced on August 26, 2026, that the U.S. Food and Drug Administration (FDA) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent…
Revolution Medicines Receives FDA Approval for RASONQUE in Metastatic Pancreatic Adenocarcinoma - Aug 5, 2026 · medium impact
Revolution Medicines, Inc. announced its financial results for the quarter ended June 30, 2026, and provided an update on corporate progress. The company reported that the U.S. FDA accepted its New Drug Application (NDA) for daraxonrasib for the treatment of previously treated metastatic pancreatic cancer.…
Revolution Medicines Files NDA for Daraxonrasib and Receives Breakthrough Therapy Designation - Jun 22, 2026 · high impact
On June 18, 2026, Revolution Medicines, Inc. announced that Dr. Steve Kelsey, its President of Research and Development, intends to retire effective January 4, 2027. Dr. Kelsey will transition to a new role as Senior Advisor to the CEO starting July 1, 2026. The company also held its annual meeting of stockholders on…
Revolution Medicines Announces Planned Retirement of President and Key Executive Changes - May 6, 2026 · high impact
Revolution Medicines, Inc. announced its financial results for the quarter ended March 31, 2026, highlighting significant improvements in overall survival for patients with previously treated metastatic pancreatic cancer from the RASolute 302 trial of daraxonrasib. The company also reported strengthened financial…
Revolution Medicines Announces Positive Daraxonrasib Trial Results and Strong Financial Position
SEC filings in the last five years
- 47 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A